Roivant Sciences reported financial results for the fourth quarter and fiscal year ended March 31, 2026. Analysts projected a loss per share between $0.29 and $0.35. Revenue expectations for the period totaled approximately $3.7 million.
The company is currently preparing for the commercial launch of its lead drug candidate, brepocitinib. The FDA is conducting a Priority Review for the treatment. A regulatory decision is expected in the third quarter of 2026.
Management also provided progress updates on the broader pipeline, including IMVT-1402 for autoimmune indications. Market reaction continues to develop following the announcement.